Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Qatar signs deal to buy Moderna COVID-19 vaccine

Published 10/25/2020, 10:57 AM
Updated 10/25/2020, 11:00 AM
© Reuters.
PFE
-
JNJ
-
MRNA
-

DUBAI (Reuters) - Qatar has signed an agreement with drugmaker Moderna Inc (O:MRNA) to buy its potential COVID-19 vaccine as soon as it is approved and released for global use, state news agency QNA quoted a health official as saying on Sunday.

There are no internationally approved vaccines yet, but several are in advanced trials, including from Pfizer Inc (N:PFE), Johnson & Johnson (N:JNJ) and Moderna.

"Negotiating early and securing a number of agreements enhances our chances of getting sufficient quantities of the vaccine early," said Abdullatif al-Khal, chair of a national COVID-19 health group and head of infectious diseases at Hamad Medical Corporation.

He did not say how many doses Doha was requesting. Earlier this month, al-Khal said Qatar signed an agreement with Pfizer and BioNTech to supply Qatar with their vaccines.

Moderna said last month it was on track to produce 20 million doses of its vaccine by the end of the year, while maintaining its goal of readying 500 million to 1 billion doses in 2021.

© Reuters. Moderna Therapeutics seen during COVID-19 in Massachusetts

The American group is also working with Swiss group Lonza AG to scale up the manufacturing and production of its potential COVID-19 vaccine to supply markets outside the United States.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.